Lawrence E. Flaherty

8.2k citations

117 papers · 5.4k indexed · 2 hit papers · h-index 38

Impact in

Oncology top 0.5%
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
Immunology top 1%
- Immunotherapy and Immune Responses

Papers in ⓘ

Oncology 80
- CAR-T cell therapy research 29
- Cutaneous Melanoma Detection and Management 25
- Cancer Immunotherapy and Biomarkers 22
- Cancer Treatment and Pharmacology 12
Immunology 32
- Immunotherapy and Immune Responses 30

Co-authors: Vernon K. Sondak (40 shared papers)John M. Kirkwood (18 shared papers)Bruce G. Redman (24 shared papers)Jeffrey A. Sosman (19 shared papers)Marc S. Ernstoff (7 shared papers)Jon Richards (5 shared papers)Michael B. Atkins (14 shared papers)Joseph M. Unger (13 shared papers)
Journals: Journal of Clinical Oncology (44 papers)Cancer (15 papers)Investigational New Drugs (10 papers)Journal of Immunotherapy (6 papers)JNCI Journal of the National Cancer Institute (2 papers)
Partner nations: United States Canada Australia

In The Last Decade

Lawrence E. Flaherty

115 papers receiving 5.2k citations

Hit Papers

align trajectories log scale

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma 2004 · 598 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2004 Journal of Clinical Oncology
2000 Journal of Clinical Oncology

Peers

Countries citing papers authored by Lawrence E. Flaherty

Since Specialization

Citations

This map shows the geographic impact of Lawrence E. Flaherty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence E. Flaherty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence E. Flaherty more than expected).

Fields of papers citing papers by Lawrence E. Flaherty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lawrence E. Flaherty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence E. Flaherty. The network helps show where Lawrence E. Flaherty may publish in the future.

Co-authors

The 25 scholars most cited alongside Lawrence E. Flaherty, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lawrence E. Flaherty Line = papers co-authored together Lawrence E. Flaherty links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 117 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190 Journal of Clinical Oncology ·John M. Kirkwood, Joseph G. Ibrahim, Vernon K. Sondak, Jon Richards, Lawrence E. Flaherty, Marc S. Ernstoff, Thomas J. Smith, Uma Rao, Mary Steele, Ronald H. Blum Hit paper breakdown →	2000	658
2	Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma Journal of Clinical Oncology ·David F. McDermott, Meredith M. Regan, Joseph I. Clark, Lawrence E. Flaherty, Geoffrey R. Weiss, Theodore F. Logan, John M. Kirkwood, Michael S. Gordon, Jeffrey A. Sosman, Marc S. Ernstoff, Christopher Tretter, Walter J. Urba, John W. Smith, Kim Margolin, James W. Mier, Jared Gollob, Janice P. Dutcher, Michael B. Atkins Hit paper breakdown →	2004	598
3	Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group Journal of Clinical Oncology ·Michael B. Atkins, Jessie J. Hsu, Charles Lee, Gary I. Cohen, Lawrence E. Flaherty, Jeffrey A. Sosman, Vernon K. Sondak, John M. Kirkwood	2008	228
4	Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study The Lancet Oncology ·Antoni Ribas, René González, Anna C. Pavlick, Omid Hamid, Thomas F. Gajewski, Adil Daud, Lawrence E. Flaherty, Theodore F. Logan, Bartosz Chmielowski, Karl D. Lewis, Damien Kee, Peter D. Boasberg, Ming Yin, Iris T. Chan, Luna Musib, Nicholas W. Choong, Igor Puzanov, Grant A. McArthur	2014	201
5	Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. Journal of Clinical Oncology ·Kenneth J. Pienta, Bruce G. Redman, Mohamad A. Hussain, Glenn Cummings, Peggy S. Esper, C Appel, Lawrence E. Flaherty	1994	171
6	Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Overall Results of a Randomized Trial of the Southwest Oncology Group Journal of Clinical Oncology ·Vernon K. Sondak, P. Y. Liu, Ralph J. Tuthill, Raymond A. Kempf, Joseph M. Unger, Jeffrey A. Sosman, John A. Thompson, Geoffrey R. Weiss, Bruce G. Redman, James G. Jakowatz, R. Dirk Noyes, Lawrence E. Flaherty	2002	161
7	Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma Journal of Clinical Oncology ·Keith T. Flaherty, Sandra J. Lee, Fengmin Zhao, Lynn M. Schuchter, Lawrence E. Flaherty, Richard Kefford, Michael B. Atkins, Philip D. Leming, John M. Kirkwood	2012	160
8	Treatment of metastatic malignant melanoma Current Treatment Options in Oncology ·Ehab Atallah, Lawrence E. Flaherty	2005	159
9	Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Impact of HLA Class I Antigen Expression on Outcome Journal of Clinical Oncology ·Jeffrey A. Sosman, Joseph M. Unger, P. Y. Liu, Lawrence E. Flaherty, Min Soo Park, Raymond A. Kempf, John A. Thompson, Paul I. Terasaki, Vernon K. Sondak	2002	138
10	A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer Urology ·David C. Smith, Bruce G. Redman, Lawrence E. Flaherty, Lang Li, Myla Strawderman, Kenneth J. Pienta	1998	137
11	Surgical Adjuvant Active Specific Immunotherapy for Patients with Stage III Melanoma: The Final Analysis of Data from a Phase III, Randomized, Double-Blind, Multicenter Vaccinia Melanoma Oncolysate Trial Journal of the American College of Surgeons ·Marc K. Wallack, Muthukumaran Sivanandham, Charles M. Balch, Marshall M. Urist, Kirby I. Bland, Douglas R. Murray, William A. Robinson, Lawrence E. Flaherty, Jon Richards, Alfred A. Bartolucci, Les Rosen	1998	135
12	Factors Associated With Breast Cancer Clinical Trials Participation and Enrollment at a Large Academic Medical Center Journal of Clinical Oncology ·Michael S. Simon, Wei Du, Lawrence E. Flaherty, Philip A. Philip, Patricia LoRusso, Cheryl A. Miree, Daryn Smith, Diane R. Brown	2004	133
13	Chronic Oral Administration of CI-994: A Phase I Study Investigational New Drugs ·Sucharu Prakash, Brenda J. Foster, Mark Meyer, Antoinette Wozniak, Lance K. Heilbrun, Lawrence E. Flaherty, Mark M. Zalupski, Louis L. Radulovic, Manuel Valdivieso, Patricia LoRusso	2001	115
14	A phase 2 trial of complete resection for stage IV melanoma Cancer ·Jeffrey A. Sosman, James Moon, Ralph J. Tuthill, James Warneke, John T. Vetto, Bruce G. Redman, P. Y. Liu, Joseph M. Unger, Lawrence E. Flaherty, Vernon K. Sondak	2011	115
15	Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group Journal of Cancer Research and Clinical Oncology ·Kim Margolin, Michael B. Atkins, John F. Thompson, Marc S. Ernstoff, Jeffrey S. Weber, Lawrence E. Flaherty, Joseph I. Clark, Geoffrey R. Weiss, Jeffrey A. Sosman, John W. Smith, Janice P. Dutcher, Jared Gollob, Jeff Longmate, D. Johnson	2002	113
16	A phase III randomized, doúble-blind, multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma Cancer ·Marc K. Wallack, Muthukumaran Sivanandham, Charles M. Balch, Marshall M. Urist, Kirby I. Bland, Douglas R. Murray, William A. Robinson, Lawrence E. Flaherty, Jon Richards, Alfred A. Bartolucci, Les Rosen	1995	94
17	Risk Assessment in Localized Primary Cutaneous Melanoma American Journal of Clinical Pathology ·Ralph J. Tuthill, Joseph M. Unger, Pengfei Liu, Lawrence E. Flaherty, Vernon K. Sondak	2002	85
18	Randomized Trial of Adjuvant Human Interferon Gamma Versus Observation in High-Risk Cutaneous Melanoma: a Southwest Oncology Group Study JNCI Journal of the National Cancer Institute ·FL Meyskens, Kenneth J. Kopecky, Charles W. Taylor, R. Dirk Noyes, Ralph J. Tuthill, E. M. Hersh, Lynn G. Feun, James H. Doroshow, Lawrence E. Flaherty, V. K. Sondak	1995	83
19	Phase 2 study of RO4929097, a gamma‐secretase inhibitor, in metastatic melanoma: SWOG 0933 Cancer ·Sylvia M. Lee, James Moon, Bruce G. Redman, Tarek Chidiac, Lawrence E. Flaherty, Yuanyuan Zha, Megan Othus, Antoni Ribas, Vernon K. Sondak, Thomas F. Gajewski, Kim Margolin	2014	81
20	Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2–Positive Advanced Melanoma Journal of Clinical Oncology ·Jeffrey A. Sosman, Carole Carrillo, Walter J. Urba, Lawrence E. Flaherty, Michael B. Atkins, Joseph I. Clark, J. Dutcher, Kim Margolin, James W. Mier, J. Gollob, John M. Kirkwood, David J. Panka, Nancy A. Crosby, Kevin O’Boyle, Bonnie LaFleur, Marc S. Ernstoff	2008	72

About Lawrence E. Flaherty

Lawrence E. Flaherty is a scholar working on Oncology, Immunology, Cancer Research, Hematology and Molecular Biology, having authored 117 papers that have together received 5.4k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (34 papers), Immunotherapy and Immune Responses (30 papers), CAR-T cell therapy research (29 papers), Cutaneous Melanoma Detection and Management (25 papers), Cancer Immunotherapy and Biomarkers (22 papers), Cancer Treatment and Pharmacology (12 papers), Cancer therapeutics and mechanisms (9 papers) and Click Chemistry and Applications (8 papers). The work is most often cited by research in Oncology (3.5k citations), Immunology (1.7k citations), Cancer Research (615 citations), Pulmonary and Respiratory Medicine (1.2k citations) and Molecular Biology (2.4k citations). Lawrence E. Flaherty has collaborated with scholars based in United States, Canada and Australia. Frequent co-authors include Vernon K. Sondak, John M. Kirkwood, Bruce G. Redman, Jeffrey A. Sosman, Marc S. Ernstoff, Jon Richards, Michael B. Atkins, Joseph M. Unger, Ehab Atallah and Joseph G. Ibrahim. Their work appears in journals such as Journal of Clinical Oncology, Cancer, Investigational New Drugs, Journal of Immunotherapy and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact